首页> 外文期刊>European Journal of Nuclear Medicine and Molecular Imaging >131I gastric uptake with and without omeprazole in patients undergoing radioiodine therapy for differentiated thyroid carcinoma.
【24h】

131I gastric uptake with and without omeprazole in patients undergoing radioiodine therapy for differentiated thyroid carcinoma.

机译:接受和不接受奥美拉唑治疗分化型甲状腺癌接受放射碘治疗的患者的131I胃摄取。

获取原文
获取原文并翻译 | 示例
       

摘要

The European Association of Nuclear Medicine (EANM) Therapy Committee guidelines for radioiodine therapy (RAIT) for differentiated thyroid cancer recommend that "the stomach lining should be protected by liberal oral hydra-tion, and use of medication, e.g. H2-blockers, also may be helpful" [1]. Histamine H2 blockers such as cimetidine and ranitidine block secretion from the cells and increase gastric mucosal uptake. Proton pump inhibitors such as omeprazole (OM) are also commonly prescribed to alleviate stomach complaints. OM, which has effects similar to those of H2 blockers, is an inhibitor of gastric acid secretion,
机译:欧洲核医学协会(EANM)治疗委员会针对分化型甲状腺癌的放射碘治疗(RAIT)指南建议:“应通过广泛的口服水合保护胃壁,并且也应使用药物(例如H2受体阻滞剂)有帮助” [1]。组胺H2阻滞剂(例如西咪替丁和雷尼替丁)可阻止细胞分泌并增加胃粘膜摄取。质子泵抑制剂如奥美拉唑(OM)通常也被处方用于减轻胃部不适。 OM具有与H2阻滞剂相似的作用,是胃酸分泌的抑制剂,

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号